Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
CSL continues rally after strong FY26 results and announces share buyback
CSL reported FY26 total revenue of $15.8bn and an adjusted net profit after tax and depreciation and amortization of $3.1bn, both slightly above revised analyst expectations. The company expects adjusted earnings growth of around 5% for FY27 and announced a new share buyback program of A$1.1bn. Analysts subsequently raised several price targets; UBS, CLSA and Morgan Stanley upgraded their ratings, supported by stronger plasma trends, about $176m in cost savings and greater strategic flexibility following the spin-off of Seqirus. » Plus sur de.investing.com
CSL forecasts return to growth and launches A$1.1bn share buyback - shares at 6.5‑month high
CSL raised its outlook for fiscal 2027 and now expects currency‑adjusted growth in adjusted net profit after tax of around 5%, well above consensus of about 2%. For fiscal 2026 the company reported revenue of US$15.8bn, adjusted NPATA of US$3.1bn (−2%) and a reported net loss of US$2.6bn after one‑off impairments related to CSL Vifor. CSL also announced a A$1.1bn share buyback program, which lifted the share price by about 5% to A$165.88. » Plus sur de.investing.com
CSL rises 16.4% after results and outlook
CSL called 2026 a “transition year”, reporting revenue of $15.8 billion (currency‑adjusted -1%) and an adjusted NPAT‑A of $3.1 billion, while a statutory loss of $2.6 billion was caused by $6.0 billion of restructuring and impairments. Investors focused on a strong operating cash flow of $3.5 billion, a new $1.1 billion AUD share buyback program and the outlook for around 5% adjusted NPAT growth in 2027 with largely stable revenue. CSL Behring is expected to return to mid‑single‑digit revenue growth in the medium term, while Vifor, as the biggest drag for 2027, expects revenue to fall by about 25%. The stock jumped 16.4% after the announcement as the market put more weight on the outlook, cash flows and capital returns than on the accounting loss. » Plus sur de.investing.com
CSL reports billion-dollar write-downs and lowers guidance – shares plunge
Biotech company CSL announces billion-dollar write-downs and lowers its guidance, triggering a sharp share price fall. Investors fear consequences for competition in the mRNA market, and BioNTech is mentioned as a potential beneficiary. » Plus sur finanzen.net
CSL reports 81% profit decline after $1.1bn impairments – shares plunge
CSL reported a reported net profit decline of 81% to $401m in the first half of 2026 after one-off impairments totaling $1.1bn. Adjusted NPATA rose 7% to $1.9bn on revenue of $8.3bn (+4%). Management confirmed the full-year guidance, announced an increase of the share buyback to $750m and target cost savings of $500–550m by FY2028; the stock fell sharply after the announcement and is trading near its 52-week low. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 6,39 Md | - |
| Bénéfice brut | 2,84 Md | - |
| Bénéfice net | -2,57 Md | - |
| EBITDA | 1,69 Md | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 59,87 Md € |
Nombre d'actions | 479,88 M |
Plus haut/bas sur 52 semaines | 129,36 € - 58,23 € |
Rendement du dividende | 2,02 % |
Dividendes TTM | 2,48 € |
Bêta | 0,08 |
Ratio P/E | -25,87 |
Ratio PEG | 0,14 |
Ratio P/B | 4,43 |
Ratio P/S | 4,17 |
Profil de l'entreprise
CSL Limited fait de la recherche, développe, fabrique, commercialise et distribue des produits biopharmaceutiques et connexes en Australie, aux États-Unis, en Allemagne, au Royaume-Uni, en Suisse, en Chine et à l'international. La société exerce ses activités à travers deux segments, CSL Behring et Seqirus. Le segment CSL Behring propose des thérapies plasmatiques, telles que des produits plasmatiques et des produits recombinants destinés au traitement de l'immunodéficience, des troubles de la coagulation, de l'angiœdème héréditaire, du déficit en alpha-1 antitrypsine et des troubles neurologiques. Ce segment mène également des recherches sur les thérapies plasmatiques et non plasmatiques, et perçoit des redevances et des licences issues de la commercialisation de sa propriété intellectuelle. Le segment Seqirus fabrique et distribue des produits biothérapeutiques non plasmatiques, et développe des produits liés à la grippe. CSL Limited a été fondée en 1916 et son siège social se trouve à Parkville, en Australie.
| Nom | CSL |
| PDG | Gordon Naylor DipCompSc |
| Siège social | Melbourne,
vic Australie |
| Site web | |
| Secteur | Santé |
| Industrie | Biotechnologie |
| Introduction en bourse | 01/06/1994 |
| Employés | 29 000 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
Pnk | CMXHF |
Australian Securities Exchange Ltd | CSL.AX |
Frankfurt | CSJ.F |
Düsseldorf | CSJ.DU |
Hamburg | CSJ.HM |
SIX | CSL.SW |
München | CSJ.MU |